Correction: Structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over βarrestin2 signaling bias (ACS Chemical Neuroscience (2015) 6:8 (1411-1419) DOI: 10.1021/acschemneuro.5b00092);Structure-Activity Relationship Studies of Functionally Selective Kappa Opioid Receptor Agonists that Modulate ERK 1/2 Phosphorylation while Preserving G Protein over βarrestin2 Signaling Bias

ACS Chemical Neuroscience

Volumn 6, Issue 8, 2015, Pages 1411-1419

  Lovell, Kimberly M ^a   Frankowski, Kevin J ^b   Stahl, Edward L ^a   Slauson, Stephen R ^b   Yoo, Euna ^b   Prisinzano, Thomas E ^b   Aubé, Jeffrey ^b   Bohn, Laura M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

arrestin; biased agonism; Functional selectivity; G protein coupling; GPCR; MAP kinase

Indexed keywords

1,2,4 TRIAZOLE DERIVATIVE; 2 [5 [(4 BROMOBENZYL)THIO] 4 (FURAN 2 YLMETHYL) 4H 1,2,4 TRIAZOL 3 YL)PYRIDINE; 2 [5 [(4 BROMOBENZYL)THIO] 4 (PYRIDIN 3 YLMETHYL) 4H 1,2,4 TRIAZOL 3 YL]PYRIDINE; 2 [5 [(4 BROMOBENZYL)THIO] 4 (THIOPHEN 2 YLMETHYL) 4H 1,2,4 TRIAZOL 3 YL]PYRIDINE; 2 [5 [(4 IODOBENZYL)THIO] 4 (FURAN 2 YLMETHYL) 4H 1,2,4 TRIAZOL 3 YL]PYRIDINE; 2 [5 [(4 IODOBENZYL)THIO] 4 (PYRIDIN 3 YLMETHYL) 4H 1,2,4 TRIAZOL 3 YL]PYRIDINE; 2 [5 [(4 IODOBENZYL)THIO] 4 (THIOPHEN 2 YLMETHYL) 4H 1,2,4 TRIAZOL 3 YL]PYRIDINE; 2 [5 [[2 CHLORO 5 (TRIFLUOROMETHYL)BENZYL]THIO] 4 (FURAN 2 YL METHYL) 4H 1,2,4 TRIAZOL 3 YL]PYRIDINE; 2 [5 [[2 CHLORO 5 (TRIFLUOROMETHYL)BENZYL]THIO] 4 (PYRIDIN 3 YLMETHYL) 4H 1,2,4 TRIAZOL 3 YL]PYRIDINE; 2 [5 [[2 CHLORO 5 (TRIFLUOROMETHYL)BENZYL]THIO] 4 (THIOPHEN 2 YLMETHYL) 4H 1,2,4 TRIAZOL 3 YL]PYRIDINE; BETA ARRESTIN 2; GUANINE NUCLEOTIDE BINDING PROTEIN; KAPPA OPIATE RECEPTOR AGONIST; MITOGEN ACTIVATED PROTEIN KINASE 1; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; BENZENEACETAMIDE DERIVATIVE; BETA ARRESTIN; KAPPA OPIATE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 3; NARCOTIC ANALGESIC AGENT; PYRROLIDINE DERIVATIVE; RECOMBINANT PROTEIN; RETINA S ANTIGEN;

ANIMAL CELL; ARTICLE; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; AGONISTS; ANIMAL; CHEMISTRY; CHO CELL LINE; CRICETULUS; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; METABOLISM; PHOSPHORYLATION;

ANALGESICS, OPIOID; ANIMALS; ARRESTINS; BENZENEACETAMIDES; BETA-ARRESTINS; CHO CELLS; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; GTP-BINDING PROTEINS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PYRROLIDINES; RECEPTORS, OPIOID, KAPPA; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84939787218     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.7b00157     Document Type: Erratum

References (39)

1. Pasternak, G. W. (1980) Multiple opiate receptors: [3H]Ethylketocyclazocine receptor binding and ketocyclazocine analgesia Proc. Natl. Acad. Sci. U.S.A. 77, 3691-1694
2. Vonvoigtlander, P. F., Lahti, R. A., and Ludens, J. H. (1983) U-50,488: A selective and structurally novel non-mu (kappa) opioid agonist J. Pharmacol. Exp. Ther. 224, 7-12
3. Dykstra, L. A., Gmerek, D. E., Winger, G., and Woods, J. H. (1987) Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects J. Pharmacol. Exp. Ther. 242, 413-420
4. Millan, M. J. (1989) Kappa-opioid receptor-mediated antinociception in the rat. I. Comparative actions of mu- and kappa-opioids against noxious thermal, pressure and electrical stimuli J. Pharmacol. Exp. Ther. 251, 334-341
5. Glick, S. D., Maisonneuve, I. M., Raucci, J., and Archer, S. (1995) Kappa opioid inhibition of morphine and cocaine self-administration in rats Brain Res. 681, 147-152
6. Negus, S. S., Mello, N. K., Portoghese, P. S., and Lin, C. E. (1997) Effects of kappa opioids on cocaine self-administration by rhesus monkeys J. Pharmacol. Exp. Ther. 282, 44-55
7. Schenk, S., Partridge, B., and Shippenberg, T. S. (1999) U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking Psychopharmacology 144, 339-346
8. Van't Veer, A., Bechtholt, A. J., Onvani, S., Potter, D., Wang, Y., Liu-Chen, L. Y., Schutz, G., Chartoff, E. H., Rudolph, U., Cohen, B. M., and Carlezon, W. A., Jr. (2013) Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity Neuropsychopharmacology 38, 1585-1597
9. Walsh, S. L., Geter-Douglas, B., Strain, E. C., and Bigelow, G. E. (2001) Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans J. Pharmacol. Exp. Ther. 299, 147-158
10. Land, B. B., Bruchas, M. R., Schattauer, S., Giardino, W. J., Aita, M., Messinger, D., Hnasko, T. S., Palmiter, R. D., and Chavkin, C. (2009) Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking Proc. Natl. Acad. Sci. U. S. A. 106, 19168-19173
11. Aldrich, J. V., Patkar, K. A., and McLaughlin, J. P. (2009) Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action Proc. Natl. Acad. Sci. U. S. A. 106, 18396-18401
12. Bodkin, J. A., Zornberg, G. L., Lukas, S. E., and Cole, J. O. (1995) Buprenorphine treatment of refractory depression J. Clin. Psychopharmacol. 15, 49-57
13. Knoll, A. T., Muschamp, J. W., Sillivan, S. E., Ferguson, D., Dietz, D. M., Meloni, E. G., Carroll, F. I., Nestler, E. J., Konradi, C., and Carlezon, W. A., Jr. (2011) Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats Biol. Psychiatry 70, 425-433
14. Mague, S. D., Pliakas, A. M., Todtenkopf, M. S., Tomasiewicz, H. C., Zhang, Y., Stevens, W. C., Jr., Jones, R. M., Portoghese, P. S., and Carlezon, W. A., Jr. (2003) Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats J. Pharmacol. Exp. Ther. 305, 323-330
15. Kardon, A. P., Polgar, E., Hachisuka, J., Snyder, L. M., Cameron, D., Savage, S., Cai, X., Karnup, S., Fan, C. R., Hemenway, G. M., Bernard, C. S., Schwartz, E. S., Nagase, H., Schwarzer, C., Watanabe, M., Furuta, T., Kaneko, T., Koerber, H. R., Todd, A. J., and Ross, S. E. (2014) Dynorphin acts as a neuromodulator to inhibit itch in the dorsal horn of the spinal cord Neuron. 82, 573-586
16. Phan, N. Q., Lotts, T., Antal, A., Bernhard, J. D., and Stander, S. (2012) Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: A literature review Acta Derm.-Venereol. 92, 555-560
17. Inan, S., Dun, N. J., and Cowan, A. (2009) Nalfurafine prevents 5′-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5′-guanidinonaltrindole-elicited scratching behavior in mice Neuroscience 163, 23-33
18. Inan, S. and Cowan, A. (2004) Kappa opioid agonists suppress chloroquine-induced scratching in mice Eur. J. Pharmacol. 502, 233-237
19. Knoll, A. T. and Carlezon, W. A., Jr. (2010) Dynorphin, stress, and depression Brain Res. 1314, 56-73
20. Land, B. B., Bruchas, M. R., Lemos, J. C., Xu, M., Melief, E. J., and Chavkin, C. (2008) The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system J. Neurosci. 28, 407-414
21. Pfeiffer, A., Brantl, V., Herz, A., and Emrich, H. M. (1986) Psychotomimesis mediated by kappa opiate receptors Science 233, 774-776
22. Roth, B. L., Baner, K., Westkaemper, R., Siebert, D., Rice, K. C., Steinberg, S., Ernsberger, P., and Rothman, R. B. (2002) Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist Proc. Natl. Acad. Sci. U. S. A. 99, 11934-11939
23. Bruchas, M. R. and Chavkin, C. (2010) Kinase cascades and ligand-directed signaling at the kappa opioid receptor Psychopharmacology 210, 137-147
24. White, K. L., Scopton, A. P., Rives, M. L., Bikbulatov, R. V., Polepally, P. R., Brown, P. J., Kenakin, T., Javitch, J. A., Zjawiony, J. K., and Roth, B. L. (2014) Identification of novel functionally selective kappa-opioid receptor scaffolds Mol. Pharmacol. 85, 83-90
25. Schmid, C. L., Streicher, J. M., Groer, C. E., Munro, T. A., Zhou, L., and Bohn, L. M. (2013) Functional selectivity of 6′-guanidinonaltrindole (6′-GNTI) at kappa-opioid receptors in striatal neurons J. Biol. Chem. 288, 22387-22398
26. Kenakin, T. (2007) Functional selectivity through protean and biased agonism: Who steers the ship? Mol. Pharmacol. 72, 1393-1401
27. Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., Miller, K. J., Spedding, M., and Mailman, R. B. (2007) Functional selectivity and classical concepts of quantitative pharmacology J. Pharmacol. Exp. Ther. 320, 1-13
28. Mailman, R. B. (2007) GPCR functional selectivity has therapeutic impact Trends Pharmacol. Sci. 28, 390-396
29. Zhou, L., Lovell, K. M., Frankowski, K. J., Slauson, S. R., Phillips, A. M., Streicher, J. M., Stahl, E., Schmid, C. L., Hodder, P., Madoux, F., Cameron, M. D., Prisinzano, T. E., Aube, J., and Bohn, L. M. (2013) Development of functionally selective, small molecule agonists at kappa opioid receptors J. Biol. Chem. 288, 36703-36716
30. Frankowski, K. J., Hedrick, M. P., Gosalia, P., Li, K., Shi, S., Whipple, D., Ghosh, P., Prisinzano, T. E., Schoenen, F. J., Su, Y., Vasile, S., Sergienko, E., Gray, W., Hariharan, S., Milan, L., Heynen-Genel, S., Mangravita-Novo, A., Vicchiarelli, M., Smith, L. H., Streicher, J. M., Caron, M. G., Barak, L. S., Bohn, L. M., Chung, T. D., and Aube, J. (2012) Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy ACS Chem. Neurosci. 3, 221-236
31. McLennan, G. P., Kiss, A., Miyatake, M., Belcheva, M. M., Chambers, K. T., Pozek, J. J., Mohabbat, Y., Moyer, R. A., Bohn, L. M., and Coscia, C. J. (2008) Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways J. Neurochem. 107, 1753-1765
32. Bohn, L. M., Belcheva, M. M., and Coscia, C. J. (2000) Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: Evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade J. Neurochem. 74, 564-573
33. Belcheva, M. M., Clark, A. L., Haas, P. D., Serna, J. S., Hahn, J. W., Kiss, A., and Coscia, C. J. (2005) Mu and kappa opioid receptors activate ERK/MAPK via different protein kinase C isoforms and secondary messengers in astrocytes J. Biol. Chem. 280, 27662-27669
34. Bruchas, M. R., Land, B. B., Aita, M., Xu, M., Barot, S. K., Li, S., and Chavkin, C. (2007) Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria J. Neurosci. 27, 11614-11623
35. Bruchas, M. R., Macey, T. A., Lowe, J. D., and Chavkin, C. (2006) Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes J. Biol. Chem. 281, 18081-18089
36. Gregory, K. J., Hall, N. E., Tobin, A. B., Sexton, P. M., and Christopoulos, A. (2010) Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias J. Biol. Chem. 285, 7459-7474
37. Griffin, M. T., Figueroa, K. W., Liller, S., and Ehlert, F. J. (2007) Estimation of agonist activity at G protein-coupled receptors: Analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15 J. Pharmacol. Exp. Ther. 321, 1193-1207
38. Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., and Novick, S. (2012) A simple method for quantifying functional selectivity and agonist bias ACS Chem. Neurosci. 3, 193-203
39. Stahl, E. L., Zhou, L., Ehlert, F. J., and Bohn, L. M. (2015) A Novel Method for Analyzing Extremely Biased Agonism at G Protein-Coupled Receptors Mol. Pharmacol. 87, 866-877